Anzeige
Meldung des Tages: US-Goldprojekt vor dem Durchbruch: Warum Investoren jetzt aufmerksam werden

Soligenix News

Aktie
WKN:  A40DDP ISIN:  US8342236044 US-Symbol:  SNGX Branche:  Biotechnologie Land:  USA
1,125 $
-0,015 $
-1,32%
0,9619 € 10.04.26
Depot/Watchlist
Marktkapitalisierung *
4,99 Mio. €
Streubesitz
-
KGV
-
Index-Zuordnung
-

Soligenix News

02.04.26 - PR Newswire
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy ...
31.03.26 - PR Newswire
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results PR Newswire
26.03.26 - PR Newswire
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease PR Newswire
23.03.26 - PR Newswire
HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 PR Newswire
19.03.26 - PR Newswire
Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"
Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs" PR Newswire
10.03.26 - PR Newswire
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency PR Newswire
26.02.26 - PR Newswire
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease PR ...
24.02.26 - PR Newswire
Soligenix to Present at BIO Investment & Growth Summit
Soligenix to Present at BIO Investment & Growth Summit PR Newswire
12.02.26 - PR Newswire
Soligenix Details Recent Progress and Upcoming Milestones
Soligenix Details Recent Progress and Upcoming Milestones PR Newswire
18.12.25 - PR Newswire
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) PR Newswire
17.12.25 - PR Newswire
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-​to-Moderate Psoriasis PR Newswire
19.11.25 - PR Newswire
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma PR Newswire
07.11.25 - PR Newswire
Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results
Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results PR Newswire
14.10.25 - PR Newswire
Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma
Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma PR Newswire
07.10.25 - PR Newswire
Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma PR Newswire
30.09.25 - PR Newswire
Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma PR Newswire
29.09.25 - PR Newswire
Soligenix Announces Closing of $7.5 Million Public Offering
Soligenix Announces Closing of $7.5 Million Public Offering PR Newswire
26.09.25 - PR Newswire
Soligenix Announces Pricing of $7.5 Million Public Offering
Soligenix Announces Pricing of $7.5 Million Public Offering PR Newswire
23.09.25 - PR Newswire
Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor
Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor PR Newswire
04.09.25 - PR Newswire
Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses
Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses PR Newswire

Newssuche

Videos

newspaper
07.04.26 0,00%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »